Home » About Us » News » Press Release

Press Releases
Rubella IgM MAX™ Antigen - 1/11/2018

 

 

Web Version

 
 

 

 

Forward icon

 

Forward

 

 
 

JANUARY 2018

 

 

 

 

Rubella IgM MAX™ Antigen

High purity antigen for multiplex and suspension Rubella IgM assays

 

 

Rubella IgM MAX™ Antigen (#6300)

High purity native antigen extraction
  consisting of E1 & E2 proteins

 Capsid free preparation
Viral Strain HPV77 grown in VERO cells

 

Other Rubella Antigens

6075

Rubella Virus Grade III Antigen
Grown in VERO cells
Viral Strain HPV77

 

6076

Rubella Virus Grade IV Antigen
Grown in VERO cells
Viral Strain HPV77
Suitable for use in CLIA, ELISA, and WB

 

6123

Rubella Virus Grade IV PBS Antigen
Grown in Vero Cells
Viral Strain HPV77

>Request more information!

Download flyer:
>Rubella IgM MAX™ Antigen

 
 

Meridian’s next generation Rubella IgM MAX™ antigen has been designed to be free of capsid proteins to specifically reduce potential cross-reactivities that cause false positive results in Rubella IgM antibody detection assays. It is prepared by extraction of Rubella antigens from cells infected with Rubella Virus strain HPV77 using a patented process (Patent #6,670,117 and #6,872,396 B2). The final purified preparation is a high purity native antigen extraction consisting of the envelope proteins E1 and E2 in the native configuration.

Rubella IgM MAX™ is ideally suited for diagnostic assays that are quantitative, utilize bead or particle based components in a suspension, or are part of a multiplex panel. The antigen’s high purity and specificity for E1 and E2 offer significant performance benefits such as minimizing non-specific protein-protein interactions and increasing assay sensitivity.

 

 

Meet us at our next conference!

Medlab Dubai
5th – 8th February 2018
Dubai, DWTC: Zaabeel 1 – 6

> Request a meeting

CACLP 2018
15th – 20th March 2018
Chongqing International Expo Center, China

> Request a meeting

 
 

 

 
back